Frequently Asked Question
The evidence is old, small, and mixed. The best-designed human trial, in 1992, found only weak effects and concluded short-term DSIP was unlikely to be of major therapeutic benefit.1
Get notified
The vote is advisory. The decision that shapes access comes later - if and when the FDA opens a formal public comment window. Most people never hear it opened. Join the list and we'll tell you the instant it does, with step-by-step instructions to file a comment that counts.
